July 11, 2020

The Niche

Knoepfler lab stem cell blog

ACT stem cells

1 min read

What new papers and news in the stem cell sphere caught your eye? Here are some recent items that seem notable to me. Diabetes relief in mice by glucose-sensing insulin-secreting human α-cells. This paper reports cellular reprogramming to insulin-producing cells in mice. They reprogrammed α-cells with Pdx1 and MafA proteins. ‘Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease’ in Nature Neuroscience. Using IPS cells for insights. “What open chromatin features predict pluripotency?” asked and answered by the authors of this review …Read More

3 min read

An international team of stem cell scientists has replicated human therapeutic cloning to make embryonic stem cells via somatic cell nuclear transfer (SCNT). The team was led by Drs. Dong Ryul Lee of CHA Stem Cell Institute in Korea and Robert Lanza of Advanced Cell Technology (ACT) and reported the advance in the Chung, et al. paper today in the journal Cell Stem Cell entitled “Human Somatic Cell Nuclear Transfer Using Adult Cells”. The cells expressed pluripotency markers (see Figure 1A at left) and …Read More

7 min read

One of the more exciting stem cell biotechs out there today is Advanced Cell Technology (ACT). At this time ACT has the only two ES cell-based FDA-approved clinical trials ongoing and so far they have looked quite promising in terms of preliminary safety data. However, ACT has much more in the pipeline including potentially iPS cell-related products such as platelets. I interviewed ACT CEO and Chairman, Gary Rabin, to get the latest on the company and its future. I wanted to thank Gary and …Read More